Dalton WS - Search Results

1

Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis.

Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS, Tao J. Lwin T, et al. Among authors: dalton ws. Leukemia. 2009 Jan;23(1):170-7. doi: 10.1038/leu.2008.266. Epub 2008 Oct 9. Leukemia. 2009. PMID: 18843286

2

Detection of multidrug resistance gene expression in multiple myeloma.

Dalton WS. Dalton WS. Leukemia. 1997 Jul;11(7):1166-9. doi: 10.1038/sj.leu.2400724. Leukemia. 1997. PMID: 9205007 Review.

3

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R. Catlett-Falcone R, et al. Among authors: dalton ws. Immunity. 1999 Jan;10(1):105-15. doi: 10.1016/s1074-7613(00)80011-4. Immunity. 1999. PMID: 10023775 Free article.

4

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Damiano JS, et al. Among authors: dalton ws. Blood. 1999 Mar 1;93(5):1658-67. Blood. 1999. PMID: 10029595 Free PMC article.

5

Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line.

Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Shain KH, et al. Among authors: dalton ws. Leukemia. 2000 May;14(5):830-40. doi: 10.1038/sj.leu.2401776. Leukemia. 2000. PMID: 10803514

6

Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes.

Shtil AA, Turner JG, Dalton WS, Yu H. Shtil AA, et al. Among authors: dalton ws. Leuk Lymphoma. 2000 Jun;38(1-2):59-70. doi: 10.3109/10428190009060319. Leuk Lymphoma. 2000. PMID: 10811448 Review.

7

Integrin-mediated drug resistance in multiple myeloma.

Damiano JS, Dalton WS. Damiano JS, et al. Among authors: dalton ws. Leuk Lymphoma. 2000 Jun;38(1-2):71-81. doi: 10.3109/10428190009060320. Leuk Lymphoma. 2000. PMID: 10811449 Review.

8

Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation.

Damiano JS, Hazlehurst LA, Dalton WS. Damiano JS, et al. Among authors: dalton ws. Leukemia. 2001 Aug;15(8):1232-9. doi: 10.1038/sj.leu.2402179. Leukemia. 2001. PMID: 11480565

9

CD95 antigen mutations in hematopoietic malignancies.

Landowski TH, Moscinski L, Burke R, Buyuksal I, Painter JS, Goldstein S, Dalton WS. Landowski TH, et al. Among authors: dalton ws. Leuk Lymphoma. 2001 Sep-Oct;42(5):835-46. doi: 10.3109/10428190109097702. Leuk Lymphoma. 2001. PMID: 11697638 Review.

10

Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone.

Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton WS, Jove R, Yu H. Burdelya L, et al. Among authors: dalton ws. Mol Cancer Ther. 2002 Sep;1(11):893-9. Mol Cancer Ther. 2002. PMID: 12481410

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters